Advertisement

5-Fluorouracil

  • Ines Mader
  • Patrizia E. Fürst-Weger
  • Robert M. Mader
  • Elisabeth I. Semenitz
  • Robert Terkola
  • Sabine M. Wassertheurer

Keywords

Clin Oncol Drug Extravasation Erythematous Eruption Venous Access Port Central Venous System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Original articles

  1. [1]
    Cathcart-Rake WF, Mowery WE: Intrapericardial infusion of 5-fluorouracil. Cancer 67: 735–737, 1991.PubMedCrossRefGoogle Scholar
  2. [2]
    Rodier JM, Malbec L, Lauraine EP, et al: Mediastinal infusion of epirubicin and 5-fluorouracil. A complication of totally implantable central venous systems. Report of a case. J Cancer Res Clin Oncol 122: 566–567, 1996.PubMedCrossRefGoogle Scholar
  3. [3]
    Teta JB, O’Connor L: Local tissue damage from 5-fluorouracil extravasation. Oncol Nurs Forum 11: 77, 1984.PubMedGoogle Scholar
  4. [4]
    Ross WB, Morris DL, Clingan PR: Major upper gastrointestinal haemorrhage associated with hepatic arterial chemoperfusion. Aust N Z J Surg 66: 816–819, 1996.PubMedCrossRefGoogle Scholar
  5. [5]
    Manheimer F, Aranda CP, Smith RL: Necrotizing pneumonitis caused by 5-fluorouracil infusion. Cancer 70: 554–556, 1992.PubMedCrossRefGoogle Scholar
  6. [6]
    Bertelli G, Gozza A, Forno GB, et al: Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 13: 2851–2855, 1995.PubMedGoogle Scholar
  7. [7]
    Reed WP, Newman KA, Applefeld MM, et al: Drug extravasation as a complication of venous access ports. Ann Intern Med 102: 788–790, 1985.PubMedCrossRefGoogle Scholar
  8. [8]
    Seyfer AE, Solimando DA: Toxic lesions of the hand associated with chemotherapy. J Hand Surg 8: 39–42, 1983.Google Scholar
  9. [9]
    Hrushesky WJ: Serpentine supravenous 5-fluorouracil (NSC-19893) hyperpigmentation. Cancer Treat Rep 60: 639, 1976.PubMedGoogle Scholar
  10. [10]
    Pujol RM, Rocamora V, Lopez-Pousa A, et al: Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. J Am Acad Dermatol 39: 839–842, 1998.PubMedCrossRefGoogle Scholar

Secondary literature

  1. [11]
    Ignoffo RJ, Friedman MA: Therapy of local toxicities caused by extravasation of cancer chemotherapeutic drugs. Cancer Treat Rev 7: 17–27, 1980.PubMedCrossRefGoogle Scholar
  2. [12]
    Cox K, Stuart-Harris R, Abdini G, et al: The management of cytotoxicdrug extravasation: guide-lines drawn up by a working party for the Clinical Oncological Society of Australia. Med J Aust 148: 185–189, 1988.PubMedGoogle Scholar
  3. [13]
    Krämer I: Zytostatika-Paravasate-Set. Krankenhauspharmazie 13: 154–160, 1992.Google Scholar
  4. [14]
    Stanley A: Managing complications of chemotherapy. In: Allwood M, Stanley A, Wright P (eds) The Cytotoxics Handbook. Radcliffe Medical Press, 3rd edition: 105–124, 1997.Google Scholar
  5. [15]
    Schneider G: Paravasate von Zytostatika. Diagnostik und Therapie. Aina S. Schneider Verlag, 6th edition: 1–17, 1999.Google Scholar
  6. [16]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Allgemeiner Teil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: A42–44, 1997.Google Scholar
  7. [17]
    Dorr RT: Pharmacologic management of vesicant chemotherapy extravasations. In: Dorr RT, Von Hoff DD (eds) Cancer Chemotherapy Handbook. Appleton & Lange, 2nd edition: 109–118, 1994.Google Scholar
  8. [18]
    Bertelli G: Prevention and management of extravasation of cytotoxic drugs. Drug Safety 12: 245–255, 1995.PubMedCrossRefGoogle Scholar
  9. [19]
    Schneider SM, Distelhorst CW: Chemotherapy-induced emergencies. Semin Oncol 16: 572–578, 1989.PubMedGoogle Scholar
  10. [20]
    Berdel WE, Schmoll HJ, Michele T, et al: Prävention und Therapie von Paravasaten/Extravasaten. In: Schmoll HJ, Höffken K, Possinger K (eds) Kompendium Internistische Onkologie. Standards in Diagnostik und Therapie. Springer, Vol 1, 3rd edition: 1689–1701, 1999.Google Scholar
  11. [21]
    Mullin S, Beckwith MC, Tyler LS: Prevention and management of antineoplastic extravasation injury. Hosp Pharm 35: 57–76, 2000.Google Scholar
  12. [22]
    Gain M, Melzer S, Meyer-Jürshof A, et al: Fluorouracil: Behandlung von Paravasaten. In: Gain M, et al (eds) ADKA-Zytostatika-Handbuch. Verlag Heiner Biller, Vol 1, 2nd edition: 57, 1997.Google Scholar
  13. [23]
    Barth J: Paravasate und deren Behandlung. In: Barth J (ed) ZytostatikaHerstellung in der Apotheke. Deutscher Apotheker Verlag, chapter VI-3: 1–9, 2000.Google Scholar
  14. [24]
    Dorr RT: Antidotes to vesicant chemotherapy extravasations. Blood Rev 4: 41–60, 1990.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Wien 2003

Authors and Affiliations

  • Ines Mader
    • 1
  • Patrizia E. Fürst-Weger
    • 2
  • Robert M. Mader
    • 3
  • Elisabeth I. Semenitz
    • 4
  • Robert Terkola
    • 5
  • Sabine M. Wassertheurer
    • 6
  1. 1.Austrian Breast and Colorectal Cancer Study GroupViennaAustria
  2. 2.SMZ FloridsdorfKrankenhaus und GeriatriezentrumViennaAustria
  3. 3.Clinical Division of Oncology, Department of Medicine IUniversity HospitalViennaAustria
  4. 4.AnstaltsapothekeLandeskrankenhaus — Universitätskliniken InnsbruckAustria
  5. 5.Kaiser-Franz-Josef HospitalViennaAustria
  6. 6.Apotheke LKH-Univ.-Klinikum GrazAustria

Personalised recommendations